Selective transduction of cerebellar Purkinje and granule neurons using delivery of AAV-PHP.eB and AAVrh10 vectors at axonal terminal locations
Authors:
Open Access
- 13 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 947490
Abstract
Adeno-associated virus (AAV)-based brain gene therapies require precision without off-targeting of unaffected neurons to avoid side effects. The cerebellum and its cell populations, including granule and Purkinje cells, are vulnerable to neurodegeneration; hence, conditions to deliver the therapy to specific cell populations selectively remain challenging. We have investigated a system consisting of the AAV serotypes, targeted injections, and transduction modes (direct or retrograde) for targeted delivery of AAV to cerebellar cell populations. We selected the AAV-PHP.eB and AAVrh10 serotypes valued for their retrograde features, and we thoroughly examined their cerebellar transduction pattern when injected into lobules and deep cerebellar nuclei. We found that AAVrh10 is suitable for the transduction of neurons in the mode highly dependent on placing the virus at axonal terminals. The strategy secures selective transduction for granule cells. The AAV-PHP.eB can transduce Purkinje cells and is very selective for the cell type when injected into the DCN at axonal PC terminals. Therefore, both serotypes can be used in a retrograde mode for selective transduction of major neuronal types in the cerebellum. Moreover, ourin vivotransduction strategies are suitable for pre-clinical protocol development for gene delivery to granule cells by AAVrh10 and Purkinje cells by AAV-PHPeB.Keywords
Funding Information
- E-Rare
- National Ataxia Foundation
This publication has 60 references indexed in Scilit:
- Consensus Paper: Current Views on the Role of Cerebellar Interpositus Nucleus in Movement Control and EmotionThe Cerebellum, 2013
- Whole Animal Perfusion Fixation for RodentsJournal of Visualized Experiments, 2012
- Extensive Methylation of Promoter Sequences Silences Lentiviral Transgene Expression During Stem Cell Differentiation In VivoMolecular Therapy, 2012
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADCMolecular Therapy, 2010
- Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cellsEMBO Reports, 2009
- AAV8, 9, Rh10, Rh43 Vector Gene Transfer in the Rat Brain: Effects of Serotype, Promoter and Purification MethodMolecular Therapy, 2008
- Genome-wide atlas of gene expression in the adult mouse brainNature, 2006
- Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brainMolecular Therapy, 2006
- Optimization of Gene Transfer into Neonatal Rat Cardiomyocytes and Unmasking of Cytomegalovirus Promoter SilencingDNA and Cell Biology, 2005